Exemestane 25mg Tablets

Exemestane 25mg is an aromatase inhibitor used for hormone-sensitive breast cancer in postmenopausal women. It is used in selected early breast cancer treatment plans after tamoxifen, and in advanced disease that has progressed after previous hormonal therapy.
Take the tablet once daily after a meal, at a consistent time. Treatment may continue for years in an adjuvant plan. If a dose is missed, take it when remembered unless the next dose is near; do not take two doses together.
Exemestane irreversibly inhibits aromatase, the enzyme that converts androgens to oestrogens. Lower oestrogen availability reduces stimulation of hormone-sensitive breast cancer cells.
Hot flushes, sweating, joint pain, fatigue, headache, nausea or sleep disturbance can occur. Bone mineral density may fall, increasing fracture risk. Severe breathlessness, allergic swelling or significant liver-related symptoms need prompt assessment.
Bone density and vitamin D status are important during treatment. Oestrogen-containing medicines can oppose its action, while rifampicin, phenytoin and other strong enzyme inducers can lower exposure. Pregnancy and breastfeeding must be avoided during treatment.
Provides endocrine control of hormone-dependent cancer and can reduce recurrence risk in an appropriate adjuvant treatment sequence. The benefit depends on the tumour's hormone sensitivity and treatment setting.
It is endocrine therapy rather than conventional cytotoxic chemotherapy. It reduces an oestrogen signal that some breast cancers depend on for growth.
The medicines block oestrogen signalling in different ways. Switching after a defined tamoxifen period is one established adjuvant strategy for eligible postmenopausal patients.
Lower oestrogen levels can accelerate bone loss. Bone-density measurements and vitamin D assessment help identify when additional bone protection is needed.
Oestrogen-containing therapy can interfere with the purpose of exemestane. Nonhormonal approaches may be considered for troublesome menopausal symptoms.
No. Adjuvant treatment is intended to reduce future recurrence risk, not just treat symptoms. Feeling well does not show whether microscopic cancer cells remain.
Aromatase: an enzyme involved in oestrogen production; Hormone-sensitive cancer: a tumour whose growth is influenced by hormonal signals; Adjuvant therapy: treatment given after primary treatment to reduce recurrence; Bone mineral density: a measure used to assess bone strength; AR: Exemestane 25mg أقراص; FR: Exemestane 25mg comprimés; PT: Exemestane 25mg comprimidos; ES: Exemestane 25mg comprimidos; RU: Exemestane 25mg таблетки; ID: Exemestane 25mg tablet; VI: Exemestane 25mg viên nén; MS: Exemestane 25mg tablet; TL: Exemestane 25mg tableta; ZH-SG: Exemestane 25mg 片剂
International B2B Enquiry
Send a structured B2B enquiry for Exemestane 25mg Tablets under Oncology Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Exemestane 25mg Tablets